Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.
Also called NCT02334254
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 420 participants
- Sponsor
- Registry
-
NCT02334254
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02334254. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- rivaroxaban and ticagrel therapy
- Intervention (Drug)
- triple antithrombotic regimen with warfarin, asipirin and clopidogrel
- Lead sponsor
- Beijing Anzhen Hospital
Record details
- Record id
cardio:ct-nct02334254- Content hash
5949e2b0ea6f2a4b67c4deee6934fce0cbc4c6c3a2c95df8e8f3d093dc399ffd